Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterology 2021 June;67(2) > Minerva Gastroenterology 2021 June;67(2):151-63

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  LIVER ELASTOGRAPHY 

Minerva Gastroenterology 2021 June;67(2):151-63

DOI: 10.23736/S2724-5985.20.02793-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of liver and spleen elastography in advanced chronic liver disease

Elton DAJTI 1, Giovanni MARASCO 1, Federico RAVAIOLI 1, Luigina V. ALEMANNI 1, Benedetta ROSSINI 1, Luigi COLECCHIA 1, Amanda VESTITO 1, Davide FESTI 1, Antonio COLECCHIA 2

1 Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; 2 Unit of Gastroenterology, Borgo Trento University Hospital of Verona, Verona, Italy



Portal hypertension is the main driver of complications in patients with advanced chronic liver disease (ACLD). In the last decade, many non-invasive tests, such us liver and spleen elastography, have been proposed and validated for the identification of patients with clinically significant portal hypertension (CSPH) and its complications, mainly hepatic decompensation and liver-related morbidity and mortality. Moreover, elastography accurately stratifies for the risk of HCC development, HCC recurrence and decompensation after liver surgery. Recent studies suggest a role of SSM in monitoring response to treatments and interventions in ACLD, such as viral eradication, non-selective beta-blockers and transjugular intrahepatic portosystemic shunt placement. However, one of the most indications to perform elastography in ACLD still remains the screening for esophageal varices. In fact, according to the Baveno VI consensus, liver stiffness measurement (LSM) <20 kPa and platelet count >150,000/mm3 can safely identify patients at low risk of varices requiring treatment (VNT) and could therefore avoid invasive upper invasive endoscopy; LSM>20-25 kPa can accurately rule-in CSPH in patients with viral etiology. Spleen stiffness measurement (SSM) is a direct surrogate of portal hypertension and has been demonstrated more accurate in predicting portal hypertension severity and VNT. A combined model including Baveno VI Criteria and SSM (≤46 kPa) can significantly increase the number of spared endoscopies (>40-50%), maintaining a low (<5%) of missed VNT.


KEY WORDS: Liver; Spleen; Hypertension, portal; Carcinoma, hepatocellular; Liver cirrhosis

inizio pagina